Complement and microglia mediate early synapse loss in Alzheimer mouse models.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and mechanistic laboratory study with no human data.
PubMed 27033548 · doi:10.1126/science.aad8373
What was done
Investigated the role of classical complement cascade proteins (C1q, C3) and the microglial complement receptor CR3 in synapse loss using mouse models of Alzheimer's disease. Researchers assessed C1q localization relative to plaque deposition, tested whether blocking C1q, C3, or CR3 altered microglial phagocytosis and synapse loss, and evaluated the requirement of C1q for soluble amyloid-beta oligomer-induced synaptic toxicity and hippocampal long-term potentiation deficits.
What was found
The abstract reports directional findings without numerical values or effect sizes. C1q increased and associated with synapses prior to overt amyloid plaque deposition. Inhibiting C1q, C3, or CR3 reduced phagocytic microglia counts and mitigated early synapse loss. C1q was required for soluble amyloid-beta oligomers to impair synapses and hippocampal long-term potentiation, and microglia engulfed synaptic material in a CR3-dependent manner upon amyloid-beta exposure.
Why it matters
Shows that developmental synaptic pruning mechanisms mediated by complement and microglia are aberrantly reactivated early in Alzheimer's pathology prior to plaque deposition, identifying a potential upstream target for therapeutic intervention.
Limits
All findings derive from mouse models and experimental amyloid-beta exposures; direct applicability to human Alzheimer's disease progression is not established in this report. The abstract does not disclose sample sizes, specific quantitative metrics, variance, or long-term cognitive outcomes.
Cited by
- supports In rodent models of Alzheimer's disease, microglial activity is required for beta-amyloid-mediated synapse loss and neuropathology.